Nick Paul Taylor

The FDA labeled BD's safety notice as a Class I event. The warning comes amid several actions from the agency on the safety of syringes.

After gaining market share during the Philips recall, Resmed can keep growing by stimulating demand through marketing initiatives and new products, William Blair analysts wrote.

The unmet need in non-alcoholic steatohepatitis (NASH) is getting bigger and bigger. In the decade up to 2032, the number of diagnosed cases in seven major markets is forecast to grow by 4.5 million, creating a bigger pie for the drugmakers that ultimately crack the troublesome indication.

UK Biobank has made deidentified whole genome sequencing (WGS) data on 500,000 people available, enabling researchers around the world to analyze the genomics results alongside 15 years of health data on the individuals.

Roche's pitch to reset the standard of care in a breast cancer population has cleared a late-phase hurdle.

Salix Pharmaceuticals is putting a new date in the disease awareness calendar. Working with two nonprofits, the drugmaker has declared Dec. 5

Another day, another artificial intelligence (AI) deal.

Chiesi is working with the BBC to show off its climate-conscious credentials,

The comment period for the proposed rule closed with more than 19,600 submissions. The American Clinical Laboratory Association outlined “grave concerns” in a 107-page document.

The company shared “reinforced guidance” to mitigate the risk of underdosing and interruptions to treatment.